Yes, the patient can receive the Invega injection the day after taking oral paliperidone
After two weeks of oral paliperidone bridging, the patient can safely receive the Invega (paliperidone palmitate) injection the next day without any additional waiting period. The oral formulation will not interfere with the injection, and no washout period is required.
Rationale for Safe Transition
The FDA-approved prescribing information for Invega explicitly addresses this scenario. When initiating paliperidone palmitate, "paliperidone palmitate treatment can be initiated the day after discontinuing previous oral antipsychotic treatment" 1. This applies to oral paliperidone as well, since it is the same active drug.
Key Pharmacokinetic Considerations
- Oral paliperidone has a terminal elimination half-life of approximately 23 hours 1
- Steady-state concentrations are attained within 4-5 days of oral dosing 1
- After two weeks of oral therapy, the patient has achieved steady-state levels
- The injection can be given while oral medication is still in the system without safety concerns
Recommended Approach for This Patient
Since this patient missed their scheduled injection and has been bridged with oral paliperidone for 2 weeks:
If the missed injection was ≤6 weeks ago:
- Resume with the maintenance dose (typically 75-150 mg eq monthly) 2, 3
- Administer in deltoid or gluteal muscle
- No additional oral supplementation needed
If the missed injection was >6 weeks ago:
- Re-initiation dosing may be required 3
- Consider: 150 mg eq (day 1) followed by 100 mg eq (day 8), both deltoid 1, 2, 3
- However, since the patient has been on oral paliperidone for 2 weeks, therapeutic levels are already present
- Clinical judgment should guide whether full re-initiation is necessary versus resuming maintenance dosing
Important Clinical Considerations
The two-week oral bridge was appropriate management for the missed injection. Research demonstrates that bridging patients when converting from oral to injectable formulations is associated with reductions in hospitalization days 4. This is particularly important for patients who were on higher doses.
Common Pitfall to Avoid
Do not delay the injection unnecessarily. The oral paliperidone has already established therapeutic drug levels over the past two weeks. Waiting beyond the next day provides no additional benefit and risks a gap in coverage as oral medication levels decline (half-life ~23 hours).
Monitoring After Injection
- The patient should continue to be monitored for efficacy and tolerability
- No additional oral supplementation is needed after the injection 1, 2, 3
- The injection will provide sustained release over the monthly dosing interval
Bottom line: Proceed with the Invega injection the next day. The oral paliperidone taken the day before does not contraindicate or delay the injection.